Ovarian Cancer Competition Accelerates With Clovis Drug Data

Updated on

Clovis Oncology Inc.’s experimental drug shrunk tumors in 82 percent of women with a certain type of deadly ovarian cancer, results that offer new promise for patients and promise to heat up the rivaly between the small Colorado biotech and U.K. drug giant AstraZeneca Plc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.